Capecitabine Tablet, Film Coated
Product Images NDC 70756-816

8 FDA label images from Lifestar Pharma Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 70756-816). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lifestar Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Capecitabine-01 (Capecitabine 01)

Capecitabine-01 (Capecitabine 01)
Chemical structure of capecitabine, displaying its molecular arrangement with rings, hydroxyl groups, and a fluorine atom, corresponding to the active ingredient capecitabine.*
FDA Label Image

Figure-01 (Newfig 1)

Figure-01 (Newfig 1)
A Kaplan-Meier survival curve graph illustrating disease-free survival over time (months since randomization) for two treatment groups: 5-FU + Leucovorin and Capecitabine. The y-axis represents survival probability, and the x-axis shows months since randomization up to 96 months. Group sizes at risk are detailed along the bottom.*
FDA Label Image

Figure-02 (Newfig 2)

Figure-02 (Newfig 2)
A Kaplan-Meier survival curve comparing overall survival between two treatment groups: 5-FU + Leucovorin and Capecitabine. The x-axis shows months since randomization, and the y-axis shows survival probability. The chart displays survival trends over time for all randomized patients in the X-ACT study.*
FDA Label Image

Figure-03 (Newfig 3)

Figure-03 (Newfig 3)
A Kaplan-Meier survival curve chart comparing overall survival probabilities for two treatment groups over time in days. The groups are 5-FU + Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/m2 twice daily intermittent. The y-axis shows estimated survival probability ranging from 0 to 1, and the x-axis shows time in days up to 1500.*
FDA Label Image

Figure-04 (Newrevfig 4)

Figure-04 (Newrevfig 4)
A Kaplan-Meier curve estimating time to disease progression in metastatic breast cancer from Study SO14999. The graph compares two treatment groups over time in days, showing estimated probability on the vertical axis and time on the horizontal axis. The groups are labeled as Docetaxel 100 mg/sqm every 3 weeks, and Capecitabine 1250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks.*
FDA Label Image

Fig 5 (Newfig 5)

Fig 5 (Newfig 5)
A Kaplan-Meier survival estimate chart depicting survival probability over time in days for metastatic breast cancer patients under different treatment groups. The graph compares Decetaxel, Gemcitabine, and Vinorelbine treatments with estimated survival probabilities decreasing over time.*
FDA Label Image

Cape_tabs_150mg (Newcapecitabine Tablets 150 mg 1200024384 V00)

Cape_tabs_150mg (Newcapecitabine Tablets 150 mg 1200024384 V00)
Capecitabine Tablets USP 150 mg film-coated tablets package label. The label indicates oral route, prescription use only, and a quantity of 60 tablets. It includes storage instructions and manufacturer details for Lifestar Pharma LLC and Reliance Life Sciences Pvt. Ltd.*
FDA Label Image

Cape_tabs_500mg (Newrevcapecitabine Tablets 500 mg 1200024383 V00)

Cape_tabs_500mg (Newrevcapecitabine Tablets 500 mg 1200024383 V00)
Label for Capecitabine Tablets, USP 500 mg oral film-coated tablets by Lifestar Pharma LLC. The label indicates 120 tablets per bottle, prescription only. It includes storage instructions, a dosage caution not to crush or cut tablets, and manufacturing details including Reliance Life Sciences Pvt. Ltd., India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.